American Board of Internal Medicine home page

Initial Certification indicates that physicians have met rigorous standards through intensive study, accredited training and evaluation and that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care.

MOC is a professionally determined standard that attests that an internist is staying current in knowledge and practice throughout his/her career.

For more than 75 years, Certification by ABIM has stood for the highest standard in internal medicine and its 20 subspecialties.

Cardiovascular Board Interventional Cardiology Exam Committee

James E. Tcheng, MD, Chair

Dr. Tcheng, a board certified internist, cardiologist, interventional cardiologist and informatician, is a Professor of Medicine and Professor of Community and Family Medicine (Informatics) at Duke University in Durham, North Carolina.

Currently, Dr. Tcheng serves as Chair of the American Board of Internal Medicine (ABIM) Cardiovascular Board Interventional Cardiology Exam Committee and is a member of the ABIM Cardiovascular Board. He is a member of the Lifelong Education Committee of the American College of Cardiology (ACC) and the ACC Publications and Editorial Coordination Committee, and the National Cardiovascular Disease Registry. He serves as Chair of the ACC Informatics and Health Information Technology Task Force and the ACC Digital Steering Committee.

He is an accomplished clinical trialist of cardiovascular therapeutics, particularly antithrombotic and interventional therapies in coronary artery disease. More recently, his career has focused on the representation and application of knowledge in electronic health record systems through the use of informatics.

Dr. Tcheng received his medical degree from Johns Hopkins University, and he completed his residency in internal medicine at Barnes Hospital, Washington University, St. Louis. He completed fellowship training in cardiology and interventional cardiology at Duke University.

As of January 2017, Dr. Tcheng reported the following external relationships:

Service on data and safety monitoring boards for the following companies, with honoraria:

  • AstraZeneca, for a study evaluating ticagrelor with aspirin versus ticagrelor alone in high-risk patients after coronary intervention.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • Philips Medical Systems, as a subject matter expert on the design and development of next generation cardiovascular information systems, receiving reimbursement for travel and honoraria.
  • Cardiovascular Systems, Inc., as a subject matter expert on the design and evaluation of clinical studies to advance the treatment of peripheral vascular and cardiovascular disease.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with reimbursement for travel expenses and honoraria:

  • International Guidelines Central, providing consultative guidance in the redesign and updating of their Web product portfolio for this publisher of Guideline “Pocket Cards.”

Work as an author or editor for following companies, with compensation as listed:

Humana Press, receiving royalties for serving as an editor for Primary Angioplasty in Acute Myocardial Infarction.

Dr. Tcheng serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Cardiology, Committee Chair of Digital Steering Committee & Informatics and Health Information Technology Task Force, and National Cardiovascular Disease Registry Board Member, and member of the Science and Quality Oversight Committee, the Data Standards Task Force, the Lifelong Learning Oversight Committee, the Cardiovascular Training Council, and the Publications and Educational Coordination Committee, receiving reimbursement for travel expenses.

Dominick J. Angiolillo, MD, PhD

Dr. Angiolillo, who is board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology, is Professor of Medicine and serves as the Director of Cardiovascular Research, Program Director, of the Interventional Cardiology Fellowship program, and Staff Cardiologist and Interventional Cardiologist at the University of Florida Health System. He joined the University of Florida College of Medicine-Jacksonville in 2004.

Much of Dr. Angiolillo's professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. He has performed seminal studies on platelet function and modulation of antiplatelet drug response, including genetic studies, for which he has received numerous national and international academic recognitions, including being named to Thomson Reuters' 2014 and 2015 list of The World's Most Influential Scientific Minds. He has also been a key investigator in the clinical development of numerous novel antithrombotic agents. His success in obtaining extramural funding has allowed to him to develop one of the most active clinical research centers in the United States.

Dr. Angiolillo has authored more than 300 peer-reviewed articles and 30 book chapters, and he is the editor of his own textbook on antithrombotic medicine. He has also been invited to deliver numerous lectures across the globe. In addition to holding active membership in many cardiovascular societies in the Unites States and Europe, Dr. Angiolillo is on the editorial board of numerous cardiovascular journals and acts as a scientific reviewer for many major journals and extramural funding agencies, including the National Institutes of Health and other federal funding agencies in several European countries.

Dr. Angiolillo graduated summa cum laude from the Catholic University of the Sacred Heart Medical School in Rome, Italy, where he completed training in medicine and cardiology. He subsequently pursued training in interventional cardiology at the Complutense University of Madrid in Spain. Ultimately, he received his doctoral degree in cellular and molecular cardiology.

As of January 2017, Dr. Angiolillo reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Florida, from the following companies:

  • Boehringer Ingelheim, for a trial of dabigatran use in patients with atrial fibrillation undergoing PCI.
  • Daiichi Sankyo, for a trial of edoxaban use in patients with coronary artery disease.

Attendance at investigators' meetings, with compensation as listed from the following company:

  • Capricor Therapeutics, advising on stem cell research, receiving reimbursement for travel expenses.

Service on data and safety monitoring boards for the following company, with compensation as listed:

  • CeloNova, on stent trial, receiving honoraria.

Service on a research-related expert panel or advisory board for the following companies, with compensation as listed:

  • AstraZeneca, advising on ticagrelor, receiving reimbursement for travel and honoraria.
  • Bayer, advising on a new formulation of aspirin, receiving reimbursement for travel and honoraria.
  • Bristol-Myers Squibb, advising on apixaban, receiving reimbursement for travel and honoraria.
  • Daiichi Sankyo, advising on edoxaban, receiving reimbursement for travel and honoraria.
  • Janssen, advising on rivaroxaban, receiving reimbursement for travel and honoraria.
  • New Haven Pharmaceuticals, advising on new aspirin formulation, receiving honoraria.
  • PLX Pharma, advising on aspirin formulation, receiving honoraria.
  • Sanofi, advising on clopidogrel, receiving reimbursement for travel and honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation as listed:

  • Daiichi Sankyo, working on edoxaban and prasugrel, receiving honoraria.

Work funded by educational grants from industry, from the following company with compensation as listed:

  • AstraZeneca, educational activities, receiving honoraria.

James C. Blankenship, MD, MHCM

Dr. Blankenship is a practicing, board certified interventional cardiologist at Geisinger Medical Center in Danville, Pennsylvania; Director of the Geisinger cardiology department and catheterization laboratories; and an Adjunct Professor of Medicine at Temple University Medical College.

He represents the American College of Cardiology (ACC) to the American Medical Association Relative Value Update Committee for the past 12 years and co-chairs the ACC Current Procedural Terminology/Relative Value Update Committee Task Force. Dr. Blankenship is immediate past-President of the Society for Cardiovascular Angiography and Interventions and is currently a member of the American Board of Internal Medicine Cardiovascular Board Interventional Cardiology Exam Committee. He has co-authored over 200 scientific abstracts and publications.

Dr. Blankenship earned his medical degree from Cornell University Medical College in New York. He completed his internship, residency and cardiology fellowship at the University of Michigan. In 2014, he received his master's degree in healthcare management from the Harvard School of Public Health.

As of January 2017, Dr. Blankenship reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Geisinger Medical Center, from the following companies:

  • Abbott, for a trial on absorbable stents.
  • AstraZeneca, for a trial on drugs to reduce adverse events after heart attacks.
  • GlaxoSmithKline, for a trial of post-percutaneous coronary intervention drugs to decrease adverse events.
  • Orexigen Therapeutics, for a trial of post-percutaneous coronary intervention drugs to decrease adverse events.
  • St. Jude, for a trial of a closure device for atrial septic defects.
  • Takeda, for a trial of a drug to prevent restenosis.
  • Therox, for a trial of super-saturated oxygen to minimize reperfusion injury following heart attack.

Dr. Blankenship serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Cardiology, co-Chair of committee advising the ACC on valuation of physician services, receiving reimbursement for travel expenses.
  • Society for Cardiovascular Angiography and Interventions, immediate past-President, receiving reimbursement for travel expenses.

Gregory J. Dehmer, MD

Dr. Dehmer is a Professor of Medicine at the Texas A&M University College of Medicine, Chief of Cardiology at Baylor Scott & White Health – Temple, Texas and Medical Director, Cardiovascular Services, Central Texas Division at Baylor Scott & White Health. He is board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology.

Previously, Dr. Dehmer was the director of the cardiac catheterization laboratory at the University of North Carolina (UNC) Hospitals and Professor of Medicine at the UNC School of Medicine. Before his position at UNC, he was at the University of Texas Southwestern Medical School as an Assistant Professor of Medicine and Director of the cardiac catheterization laboratory at the Dallas VA Medical Center. He a past President of the Society for Cardiovascular Angiography and Interventions and has served on the Board of Trustees of the American College of Cardiology. Currently, he is a member of the Internal Medicine Cardiovascular Board Interventional Cardiology Board Exam Committee.

Dr. Dehmer has participated on the writing committees of several national guidelines, including the Clinical Competency Statement on Cardiovascular Interventional Procedures, guidelines for coronary angiography, Expert Consensus Document for Cardiac Catheterization Laboratories, Expert Consensus Document on PCI without on-site cardiac surgery and the Appropriateness Criteria for Coronary Artery Revascularization. He is an emeritus member of the National Cardiovascular Data Registry management board. He has published more than 190 articles and book chapters and has served on the Editorial Boards of Circulation, the Journal of the American College of Cardiology and the American Journal of Cardiology. He is a master fellow of the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions.

Dr. Dehmer earned his undergraduate degree from Carroll University and medical degree from the University of Wisconsin in 1975. He completed his training in internal medicine and cardiology at the University of Texas Southwestern Medical Center at Dallas.

As of January 2017, Dr. Dehmer reported the following external relationships:

Service on data and safety monitoring boards for the following company, with compensation as listed:

  • The Medicines Company, for an international trial in patients undergoing transaortic valve replacement to determine the treatment effect of using bivalirudin instead of unfractionated heparin, receiving honoraria.

Service on a research-related expert panel or advisory board for the following company, with reimbursement for travel expenses and honoraria:

  • Consultant to the Circulatory System Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food & Drug Administration, advising the FDA on the approval of new devices. Service on other non-profit healthcare-related companies:

Dr. Dehmer serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American College of Cardiology, Chair of Public Advisory Group of the National Cardiovascular Data Registry, receiving reimbursement for travel expenses.
  • American College of Cardiology, co-Chair of Appropriate Use Task Force, receiving reimbursement for travel expenses.

John S. Douglas Jr., MD

Dr. Douglas is Professor of Medicine (Cardiology) at Emory University School of Medicine and Director of the Interventional Cardiology Fellowship Program at Emory University. Dr. Douglas is board certified in Cardiovascular Disease and Interventional Cardiology and serves on the American Board of Internal Medicine Cardiovascular Board Interventional Cardiology Exam Committee.

Dr. Douglas is the former Director of Interventional Cardiology and Director of the Cardiac Catheterization Laboratory at Emory University Hospital. He has mentored more than 100 interventional cardiology fellows and participated in many of the pivotal interventional cardiology clinical trials since 1980.

Dr. Douglas served on the Board of Trustees of The Society for Cardiovascular Angiography and Interventions and Board of Governors of the American College of Cardiology (ACC). He was ACC Governor for Georgia and received the Georgia Chapter Career Achievement Award.

Dr. Douglas is a graduate of the University of the South and Washington University School of Medicine. He received house staff training at University of North Carolina, Chapel Hill and Grady Memorial Hospital. He served in the United States Navy as a Lieutenant Commander at Camp Lejeune Marine Corps Base and An Hoa Combat Base, South Vietnam. He has been a member of the Emory University School of Medicine faculty since 1974.

As of January 2017 Dr. Douglas reported no external relationships.

James B. Hermiller Jr., MD

Dr. Hermiller serves as Director of Interventional Cardiology for St. Vincent Medical Group at St. Vincent Hospital Indianapolis and serves as Director of the Interventional Cardiology Fellowship Program at St. Vincent Hospital, Indianapolis. He is board certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology.

Dr. Hermiller is a member of the American Board of Internal Medicine Cardiovascular Disease Interventional Cardiology Exam Committee.

Dr. Hermiller graduated summa cum laude from both Miami University, Oxford, Ohio (undergraduate degree) and from The Ohio State School of Medicine, Columbus, Ohio (medical degree). Dr. Hermiller completed an internal medicine internship and residency at the National Naval Medical Center in Bethesda, Maryland, where he was also Chief Resident. He completed his cardiology fellowship at Duke University Medical Center, Durham, North Carolina.

As of January 2017, Dr. Hermiller reported the following external relationships:

Funding for clinical trial expenses and staff, paid to St. Vincent Medical Group, from the following companies:

  • Abbott Laboratories, for a trial of bioresorbable vascular stents.
  • Abbott Laboratories, for a study of the MitraClip device for patients with functional mitral regurgitation who are
  • Edwards Pharmaceutical, a study of the S3 valve for transaortic valve replacement, and the FORTIS trial for transmitral valve repair.
  • Medtronic Inc., for a study of CoreValve for transaortic valve replacement.
  • St. Jude Medical (now Abbott), for a study of the Portico valve for transaortic valve replacement
  • St. Jude Medical (now Abbott), for the AMULET trial of left atrial appendage isolation.

Service on a research-related expert panel or advisory board for the following company, with compensation as listed:

  • St. Jude Medical (now Abbott), member of Executive Committee for AMULET trial, receiving reimbursement for travel expenses.

Teaching in satellite symposia funded by the following company, with compensation as listed:

  • Abbott Laboratories, receiving reimbursement for travel expenses and honoraria.

Michael Ragosta, MD

Dr. Ragosta is a board certified cardiologist and interventional cardiologist and the Kaplan Professor of Medicine and Director, Cardiac Catheterization Laboratories at the University of Virginia Health System in Charlottesville, Virginia. He has more than 20 years of experience as an academic interventional cardiologist and is very active in medical education, clinical research and clinical practice. Clinically, he focuses on complex coronary artery disease, chronic total occlusion intervention, and valvular heart disease, particularly aortic stenosis. As an educator, Dr. Ragosta is Program Director for the Interventional Cardiology Fellowship and teaches medical students, residents and cardiology fellows on a daily basis. He is course director for several continuing medical education programs including the weekly “Cath Conference” and the “Central Virginia Cardiac Catheterization Conference”.

Dr. Ragosta is a member of the American Board of Internal Medicine Cardiovascular Board Interventional Cardiology Exam Committee. He has authored several on-line teaching activities and is the author of several durable teaching publications including “Textbook of Clinical Hemodynamics, Cardiac Catheterization: An Atlas and DVD” and “Cases in Interventional Cardiology”, as well as numerous chapters on various topics in interventional cardiology.

Dr. Ragosta is an active clinical researcher focusing on coronary physiology, novel pharmacology for coronary intervention, high risk coronary intervention and valvular heart disease. He has been a Principal Investigator or Co-Principal Investigator for numerous clinical trials involving coronary interventional pharmacology, coronary stents, fractional flow reserve and valvular heart disease. He is the author or co-author of over 100 peer-reviewed articles. He is on the editorial board of Journal of American College of Cardiology: Cardiovascular Interventions and is ad hoc reviewer for numerous prestigious journals. He also serves as Editor in Chief of SCAI.org, the website for the Society for Cardiac Angiography and Intervention.

Dr. Ragosta completed medical school at Brown University, an internal medicine residency at Yale-New Haven Hospital and both cardiology and interventional cardiology fellowships at the University of Virginia Health System.

As of January 2017, Dr. Ragosta reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Virginia, from the following companies:

  • Abbott, for a trial on stents in treatment of left main coronary artery disease.
  • Direct Flow Medical, for a trial on transcatheter aortic valve replacement.
  • Edwards, for the Sapien trial used in transaortic valve replacement.

Work funded by educational grants from industry, paid to the University of Virginia, from the following companies:

  • Cordinus Vascular Robotics, to support education related to robotic coronary intervention.
  • Elsevier, receiving compensation for authorship.
  • Society for Cardiovascular Angiography and Interventions, Editor for SCAI.org, without compensation.

Robert D. Safian, MD

Dr. Safian is the Founder and Director of the Center for Innovation and Research in Cardiovascular Diseases at Beaumont Health. He is also the Director of the Fellowship Training Program in Cardiovascular Diseases and the Director of the Fellowship Training Program in Interventional Cardiology at William Beaumont Hospital. Dr. Safian is board certified in Internal Medicine, Cardiovascular Disease, Interventional Cardiology, Vascular Medicine and Endovascular Medicine. He is Professor of Medicine at Oakland University William Beaumont School of Medicine.

Currently, Dr. Safian's major interests are in professional teaching and education; clinical research in new interventional technologies for structural, valvular and vascular diseases; and use of invasive and non-invasive imaging technologies for plaque characterization in the coronary and non-coronary vascular beds. He is a member of the American Board of Internal Medicine Cardiovascular Board Interventional Cardiology Exam Committee. He is involved in various community activities to raise awareness and philanthropic support for diagnosis and treatment of children with Crohn's disease and colitis. He is the founder of the Michigan Youth Life-Sciences Program, to provide educational and career opportunities in the life sciences to high school students in the inner cities.

Dr. Safian has published extensively, including books and original articles in the fields of interventional cardiology and endovascular medicine. He serves on numerous committees in various professional societies and on the steering committees of several research trials. He has been the recipient of several awards for teaching and clinical research.

Dr. Safian received a degree in chemistry from the University of Florida, with a minor in political science. He received his medical degree from the University of Florida, and completed residency programs in internal medicine at the University of California, San Diego, and in anatomic pathology at the University of Miami. He completed fellowship programs in cardiology and in interventional cardiology at Beth Israel Hospital-Harvard Medical School, and in vascular medicine at Duke University.

As of January 2017, Dr. Safian reported no external relationships.